News

Sarepta Therapeutics shares closed over 5.3% lower on Monday, hitting more than a nine-year low, and fell another 8.5% in ...
Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...
The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Ele­vidys, after three patients died from ...
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...
Shares of Sarepta Therapeutics plummeted nearly 30% premarket Friday following a report that a third patient has died during ...